116 results about "High risk patients" patented technology

A system and a method for scheduling an emergency procedure in response to detecting that a patient has a high probability of acute myocardial infarction. The system is able to identify patients that are suspected of having acute myocardial infarction (or acute ischemia). The system uses one or more expert software tools or algorithms to analyze received ECG records. Each software tool has logic (e.g., thresholds and/or settings) for automatic routing which is configurable by the customer via a graphical user interface. If any sufficient condition for automatic routing is satisfied, the system routes the data (including the underlying ECG record) and an alert to an electronic device which is accessible by the cardiologist “on call” via a bidirectional pager. If the cardiologist decides that the requested emergency treatment or procedure should be performed, the system accesses the schedules of all associated catheterization labs across multiple hospitals to identify a lab having optimum time-to-treatment. Then the system automatically contacts the selected catheterization lab via a network to schedule the PTCA procedure.

Colorectal cancer patients with operable tumors must decide whether to receive adjuvant therapy after surgical resection in order to reduce their chances of recurrence. Current clinical guidelines are crudely based on the stage of the disease, as well as a few other clinicopathologic features. The instant invention integrates data from these clinicopathologic features with data on multiple biomarkers using advanced informatic methods to provide a far more accurate prediction of recurrence than the current guidelines. The instant invention consists of a panel of biomarker assays plus an algorithm into which the scored biomarker data, as well as standard clinicopathologic data, is entered. A tumor sample from an individual patient is submitted for test, and an individualized report is produced with a prognostic score that accurately reflects the patient's risk of recurrence. This helps guide the patient and his/her oncologist in their choice of whether to receive adjuvant treatment. Low-risk patients are spared the unnecessary toxicities associated with cytotoxic treatments, and high-risk patients are given the best chance for a cure, maximizing both life expectancy and quality of life.

The method of the present invention is used to select high risk or co-morbid patients for participation in a care management program. An acuity score determines which patients are selected for care management.

The invention belongs to the technical field of cardio cerebrovascular rehabilitation training, and discloses a cardio cerebrovascular rehabilitation training system. The cardio cerebrovascular rehabilitation training system comprises: a blood-pressure detecting module, a pulse detecting module, a heart rate detecting module, a main control module and a training module, an analysis module, a disease warning module, a data storage module, and a display module. The system can well group the populations of the Chinese people with cardio cerebrovascular diseases based on the similarity analysis through the analysis module, and carry out targeted personalized rehabilitation treatment for different risk groups as early as possible; the disease warning module is used to timely warn and monitor the risk factors of high risk patients with cardio cerebrovascular diseases, so as to achieve timely and effectively interfere the high-risk groups.

The invention discloses a liquid medicine syringe device driven by a linear motor and a solenoid valve, wherein the liquid medicine syringe device takes an action after receiving a transmitted control command through a Bluetooth, and injects liquid medicine to muscles of a human body through the linear motor and the solenoid valve so as to achieve the injection. The liquid medicine syringe device can receive signals in a real-time manner, can protect high-risk patients, can quickly inject liquid medicine to the patients, is stable and reliable, and is convenient to carry about.

The invention relates to a freeze-drying composition of a posaconazole prodrug and a preparation method and application of the freeze-drying composition of the posaconazole prodrug. The freeze-drying composition has the advantages that the freeze-drying composition is high in water solubility, and safety of the freeze-drying composition is guaranteed due to the fact that cyclodextrins auxiliary materials need not to be added during the preparation of the freeze-drying composition; the freeze-drying composition is suitable for being used for treating various amphotericin-intolerant or refractory adult invasive fungal infections; the freeze-drying composition is used as a preventive drug for high-risk patients, the freeze-drying composition is applicable to patients above 13 years old and with impaired immunity and especially applicable to patients who have graft versus host disease (GVHD) after hematopoietic stem cell transplant, patients with leukemia and patients with long-term leukopenia due to chemotherapy; compared with control drugs such as fluconazole and itraconazole, the freeze-drying composition can effectively prevent invasive aspergillosis and can lower the mortality related to the invasive fungal infections.

The technical scheme of the invention provides a gene chip for predicting liver cancer metastasis and recurrence risk, which comprises a substrate and a probe arranged on the substrate, wherein the probe consists of 149 genes. The gene chip for predicting the liver cancer metastasis and the recurrence risk has the advantages that: due to the adoption of genome comparison research, a large sample independently proves that a prediction model can accurately predict and evaluate the metastasis potential of liver cancer patients. Therefore, postoperative survival and metastasis, and recurrence of the patient can be accurately predicted (even early liver cancer patients can be accurately predicted). The gene chip contributes to early identifying or predicting high-risk patients so as to perform intensive monitoring and effective intervention on the high-risk patients to further prolong the life of the tumor patients.

Patients with gastric carcinoma are different in survival prognosis. High-risk patients with gastric carcinoma are patients with gastric carcinoma, the mortality risks of who are high. The invention relates to a prognosis method for the patients with gastric carcinoma. The prognosis method comprises the following steps of: collecting clinical information of the patients with gastric carcinoma to be tested; and, comparing the clinical information of the patients with gastric carcinoma to be tested with preoperative evaluation indexes of the high-risk patients with gastric carcinoma so as to obtain a prognosis result of the patients with gastric carcinoma to be tested, wherein when the clinical information of the patients with gastric carcinoma to be tested accords with standards of the preoperative evaluation indexes of the high-risk patients with gastric carcinoma, the patients with gastric carcinoma to be tested are the high-risk patients with gastric carcinoma; and the preoperative evaluation indexes of the high-risk patients with gastric carcinoma includes the age older than or equal to 60 years, a body mass index of being less than 18.5 kg/m<2>, the blood albumin content of being less than 40 g/L, low cell differentiation degree and the like. In the prognosis method for the patients with gastric carcinoma provided by the invention, required information can be obtained before operation; and thus, prognosis conditions of the patients with gastric carcinoma can be evaluated before operation.

A method of guiding the care of a critically ill patient or other high risk patient, said method comprising administering an effective dose of a gastric acid stimulant or suppressant agent and then measuring for an acute change in the gastric juice pH. A patient who demonstrates a significant change in the gastric juice pH using this test can have their medical care normalized in an accelerated fashion thereby reducing the duration, intensity, and cost of their care. Conversely, a patient who is not responsive is not ready for reduced support and may require more support.

The invention discloses application of a product for detecting ceramide in preparation of a kit. The application of the kit is at least one of the following (a1)-(a3): (a1) screening or assisting in diagnosing heart failure patients; (a2) evaluating or assisting in evaluating the prognosis risk of heart failure patients; and (a3) evaluating or assisting in evaluating the adverse event risk of heart failure patients. Research results show that the ratio of plasma ceramide cer (d18: 1/16: 0) to cer (d18: 1/24: 0) is an important predictive factor for the occurrence of adverse events of heart failure in patients with heart failure at the final stage, and is independent of currently used lipid markers, which facilitates the identification of high risk patients requiring more positive therapeutic interventions.

Aptamers for use in the capture, diagnosis, enumeration and eradication of circulating tumor cells; an aptamer immobilized microfluidic chips for use in a rapid and non-invasive method of testing for cancer by capturing and detecting circulating tumor cells through the use of the aptamers immobilized microfluidic chips, and screening high risk patients for cancer thereby allowing the disease to be identified at the early stage where the prognosis of survival is the highest; and a non-invasive method of treating cancer by capturing and eradicating circulating tumor cells through the use of aptamer-photosensitizer conjugates injected into a patient's bloodstream and excited by a laser.

Disclosed are a marker composed of tissue snoRNA and a kit used for predicting the liver cancer recurrence risk. The invention discloses a marker used for predicting the postoperative recurrence risk of a patient who suffers from liver cancer. The maker is composed of one or several of the following snoRNA nucleic acid molecules: U15a, U19, ACA21, ACA31, U42b, U52 and/or ACA61. The invention further discloses a multi-gene kit for evaluating the postoperative recurrence risk of the patient who suffers from liver cancer. The kit comprises an agent for detecting the level of the following snoRNA nucleic acid molecules including U15a, U19, ACA21, ACA31, U42b, U52 and/or ACA61 in the tumor tissue of a patient who suffers from liver cancer. The kit can reflect the postoperative recurrence risk of a patient who suffers from liver cancer, allows excessive treatment to a low-risk patient to be avoided, and warns a high-risk patient. The kit is convenient for a clinician to adopt a personalized recurrence prevention scheme in time.

The invention discloses a horizontal microwave global thermal therapy device for a tumor, and relates to the technical field of medical apparatus and instruments. The thermal therapy device mainly comprises a microwave global radiation unit, an internal temperature measurement unit, a physique scanning unit, a treatment thermal insulation cabin and an intelligent data unit, and a CT (computed tomography) unit is added. The horizontal microwave global thermal therapy device is favorable for utilizing previous data accumulation, intelligently sets each control parameter through logical reasoningand intelligent computing, and reduces or avoids incision wounds for a human body by the imbedding of the internal temperature measurement unit so as to realize the accurate control of a temperaturein a body. Through the arrangement of a rotatable microwave irradiation ring and the horizontal treatment thermal insulation cabin, convenience is brought to a high risk patient to lie flatly to receive even irradiation, in addition, human body global irradiation treatment can be realized, and a purpose of global tumor treatment is achieved.

The invention discloses a portable automatic multi-drug injection device. The device can receive a wireless signal or a device button order to carry out action; the real-time mixing and the quantitative and regular injection of different injected liquid medicines is achieved by an air compressor driven by a micro motor. The portable automatic multi-drug injection device can real-time receive signals to protect a high risk patient, can quickly inject liquid medicines for patients, is stable and reliable and is convenient to carry along.

This relates to the prevention of cancer initiation. More specifically, the invention provides compositions and methods useful for altering the genetic signature in breast tissue, said alteration being correlated with a reduced risk for the development of breast cancer.

The invention relates to an arc assisting turning bed which comprises four telescopic bed legs which can be fixed; an arc bed board is fixed on the bed legs; a carbon fiber grid air cushion which is as long as the bed board is arranged on the bed board; a rotatable shaft rod is arranged at the center of the back surface of the arc bed board; bearings are arranged at two ends of the shaft rod respectively; shaft rod supporting legs are also arranged at two ends of the shaft rod respectively; and arc bed guardrails which can be pulled out are also arranged at the front side and the rear side of the bed board respectively. The arc assisting turning bed has the benefits of having simple process, being convenient to manufacture, bringing convenience for old high-risk patients to turn over, and being worth of popularization.

The invention discloses an SNP marker composition related to onset risk of brain radiation injury caused by tumor radiotherapy and application thereof. The SNP marker composition comprises 15 SNP loci. Meanwhile, a kit for predicating the onset risk of brain radiation injury caused by tumor radiotherapy is prepared, the kit is adopted to detect types of SNP markers, and the onset risk of onset risk of patients suffering from nasopharyngeal carcinoma can be more comprehensively and accurately detected estimated through clinic information of the patients. Through the adoption of the SNP marker composition to clinical applications, and adoption of protective measures in advance to high-risk patients, the SNP marker composition is beneficial to implementation of individualized treatment to thepatients, and improves the long-term survival quality of the patients suffering from nasopharyngeal carcinoma. Meanwhile, the SNP marker composition can provide a method and tactical reference for the predication of risk of normal tissue injury caused by other radiotherapies.

The invention relates to a J wave classifying method, in particular to a J wave classifying method based on a support vector machine. A blind source separating technology serves as a basis, the support vector machine serves as a main means, and automatic classification on benignant electrocardiosignal containing J waves and malignant electrocardiosignal containing J waves can be carried out. By the classification on the benignant electrocardiosignal containing the J waves and the malignant electrocardiosignal containing the J waves, high-risk patients whose electrocardiosignal contains abnormal J waves clinically can be recognized by doctors, the possibility of malignant premature bipolar syndrome, malignant arrhythmia and idiopathic ventricular fibrillation sudden death can be reduced, and a theory and practice basis is provided for accurate diagnosis on high-risk states of the J waves clinically. In the J wave classifying method based on the support vector machine, three subjects including medical science, blind source separation and machine learning are combined. The J wave classifying method based on the support vector machine belongs to frontier research hotspots in the domestic and foreign relevant field.